PTO/SB/21 (08-00) Please type a plus sign inside this box -Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 09/421,545 TRANSMITTAL Filing Date October 20, 1999 **FORM** First Named Inventor Dr. Gregory R. MUNDY Group Art Unit 1651 (to be used for all correspondence after initial filing) **Examiner Name** R. Gitomer Total Number of Pages in This Submission 3 Attorney Docket Number 432722002621 ENCLOSURES (check all that apply) Fee Transmittal Form Assignment Papers After Allowance Communication (for an Application) to Group Fee Attached Appeal Communication to Board of Drawing(s) Appeals and Interferences Amendment/Reply Appeal Communication to Group Licensing-related Papers (Appeal Notice, Brief, Reply Brief) Petition After Final Proprietary Information Petition to Convert to a Provisional Affidavits/declaration(s) Status Letter Application Power of Attorney, Revocation Extension of Time Request Other Enclosure(s) Change of Correspondence Address (please identify below) **Express Abandonment Request** 1. Summary of Interview of June Terminal Disclaimer 19, 2003 (2 pages); Information Disclosure Statement Request for Refund 2. Return Receipt Postcard. Certified Copy of Priority CD, Number of CD(s) Document(s) Response to Missing Parts/ Incomplete Application Remarks RECEIVED Response to Missing Parts under 37 CFR 1.52 or 1.53 JUL 0 9 2|003 TECH CENTER 16 00/2900 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm **MORRISON & FOERSTER LLP** Laurie L. Hill - 51,804 Individual Name Signature

hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail,	
n envelope addressed to: Commissioner for Patents, P.O. Box 1450. Alexandria, VA 22313, 1450, as the details wall,	ın
22313-1430, off the date snown below.	
ated: /-2-03 Signature	
n envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below. ated: 1-2-03 Signature: Alexandria (Marian L. Christophe	er)

Date

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: , Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below

Docket No.: 432722002621

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Gregory R. MUNDY, et al

Examiner: R. Gitomer

Application No.: 09/421,545

Group Art Unit: 1651

Filed: October 20, 1999

RECEIVED

For: INHIBITORS OF PROTEASOMAL ACTIVITY FOR STIMULATING BONE AND HAIR

JUL 0 9 2003

GROWTH

TECH CENTER 1600/2900

SUMMARY OF INTERVIEW OF JUNE 19, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

On June 19, 2003, a telephone interview was held in the above application by Examiner Michael Wityshyn and Applicants' attorney, Laurie L. Hill.

Applicants gratefully acknowledge the time and effort of Michael Wityshyn in his review of the file history of the instant application. The interview with Dr. Wityshyn was very productive and helpful to Applicants.

The substance of the interview is summarized herewith. Attorney for Applicants contacted Dr. Wityshyn requested his review of the file history with regards to the outstanding written description and enablement rejections under 35 U.S.C. § 112. After review of the file, Dr. Wityshyn withdrew the written description and enablement rejections in view of the arguments and evidence submitted by Applicants. Dr. Wityshyn also indicated that the obviousness type double

patenting rejection would be maintained until the sufficiency of the copy of the terminal disclaimer is determined. Finally, Dr. Wityshyn indicated several formal matters requiring Action from Applicants, including (1) amending the specification to include the term "peptidyl aldehyde", (2) amending the specification with regards to the amino acid sequences to provide the required SEQ ID NOs, and (3) filing a substitute declaration that includes Rossini full name and indicates the date of amendment of the specification. According to Dr. Wityshyn, if the terminal disclaimer is sufficient and no prior is discovered in the IDS 1449 forms, a Quayle action will be sent from the Office directed to the formal matters discussed above.

Dated: July 2, 2003

Respectfully submitted,

Laurie L. Hill, Ph.D.

Registration No.: 51,804 MORRISON & FOERSTER LLP 3811 Valley Centre, Suite 500 San Diego, California 92130

Telephone: (858) 720-7955 Facsimile: (858) 720-5125 Attorneys for Applicant